Comprehensive management of pressure ulcers in spinal cord injury: current concepts and future trends.
Erwin A Kruger, Marilyn Pires, Yvette Ngann...
https://pubmed.ncbi.nlm.nih.gov/24090179/Actively Recruiting
Led by Reprise Biomedical, Inc. · Updated on 2025-12-24
20
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating the Miro3D Wound Matrix, a biologic wound dressing made from pig liver tissue, to help heal difficult wounds and ulcers in adults. This post-market, proof-of-concept study focuses on wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and surgical wound openings. The study aims to understand how well Miro3D supports healing and improves quality of life when used alongside standard wound care in outpatient settings. Participants will receive weekly applications of Miro3D to their wounds for the first four weeks, alongside usual treatments like cleaning, dressing changes, offloading, and infection management. If the wound is not fully healed after four weeks, the Miro3D application frequency changes to every two weeks until healing occurs or up to twelve weeks total. The study includes a screening phase and a twelve-week treatment phase with no washout period. Throughout the study, participants will visit the clinic weekly for wound assessments, including measurements, photographs, and depth checks, and complete questionnaires about pain and quality of life. Healing progress is tracked by measuring wound size reduction and new tissue growth. Safety is closely monitored by tracking any adverse events. Participants finish the study when their wound heals or after twelve weeks and may then return to their regular doctor for follow-up care.
CONDITIONS
Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care
M
Maria Swartz
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Reprise Biomedical, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Miro3D Wound Matrix plus Standard of Care | Standard Outpatient Wound Care (No Miro3D) |
|---|---|---|
| What is it? | A sterile, acellular, three-dimensional biologic scaffold (Miro3D) derived from porcine liver tissue, used topically with standard wound care to promote healing in complex or chronic wounds. | Outpatient management of chronic wounds using guideline-supported approaches, including regular wound debridement, maintenance of a moist wound environment, infection control, and the use of topical dressings. Does not include specialized acellular or biologic matrices. |
| Role in the trial | Evaluated as the primary intervention combined with standard wound care in all enrolled participants. | Serves as the main approach for wound management in outpatient settings outside clinical trials when investigational products are not used. |
| Primary use | To support granulation tissue formation and accelerate healing in complex and chronic wounds, particularly those that are undermined or have tunnels. | To facilitate wound healing, prevent infection, reduce wound size, and improve quality of life through established outpatient wound care practices. |
| How it is given or performed | Miro3D matrix is rehydrated and placed directly onto a freshly debrided wound bed, covered with a standard dressing, and wound care is continued per clinical guidelines. | Consists of regular wound cleaning and debridement, application of moist dressings, offloading/compression when appropriate, and routine follow-up per outpatient protocols. |
| Evidence status | Currently being evaluated in early-phase clinical research. Published outcomes for Miro3D are not yet available. | Established wound care practices are supported by moderate-quality evidence, though rates of complete closure remain variable. Evidence for adjuncts beyond dressings is mixed or limited. |
| Important limitations | Limited to a small pilot group. Real-world safety, long-term outcomes, and comparative effectiveness versus other advanced therapies are not yet determined. | Healing rates for chronic wounds with standard care alone remain suboptimal. Evidence for selecting among dressing types is mixed, and improvements beyond standard protocols are modest. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 weeks or until wound closure
Participants receive weekly applications of Miro3D Wound Matrix for the first 4 weeks, followed by applications every 2 weeks until the wound is healed or up to 12 weeks. Weekly evaluations track wound healing progress, quality of life, and pain levels.
Weekly visits for up to 12 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Erwin A Kruger, Marilyn Pires, Yvette Ngann...
https://pubmed.ncbi.nlm.nih.gov/24090179/Joshua S Mervis, Tania J Phillips
https://pubmed.ncbi.nlm.nih.gov/30664905/M E Beth Smith, Annette Totten, David H Hickam...
https://pubmed.ncbi.nlm.nih.gov/23817703/Karen Bauer, Kathryn Rock, Munier Nazzal...
https://pubmed.ncbi.nlm.nih.gov/27861135/Alok Raghav, Zeeshan Ahmad Khan, Rajendra Kumar Labala...
https://pubmed.ncbi.nlm.nih.gov/29344337/William V Padula, Benjo A Delarmente
https://pubmed.ncbi.nlm.nih.gov/30693644/Reprise Biomedical, Inc.
Lead Sponsor